FDA Moves to Restrict Compounding GLP-1 Ingredients

The Food and Drug Administration said Friday it intends to restrict access to GLP-1 drug ingredients used in nonapproved compounded weight-loss products and that Hims & Hers Health Inc. could face federal enforcement, a move the agency said is aimed at curbing mass-marketed …

Related articles

You may also be interested in

Headline

Never Miss A Story

Get our Weekly recap with the latest news, articles and resources.
Cookie policy

We use our own and third party cookies to allow us to understand how the site is used and to support our marketing campaigns.